Andrew Weisenfeld

 Andrew Weisenfeld has been an investment banker since 1989. He became a partner at MTS Health Partners in January 2008 and is now one of the firm’s managing partners, primarily responsible for the development of the life sciences M&A advisory practice. Prior to joining MTS, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. He co-led the firm’s life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Mr. Weisenfeld was a managing director at J.P. Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all sectors of healthcare from the middle of 1997 to the beginning of 2003. Prior to joining Chase, he spent over five years in the M&A Group at Merrill Lynch. 

Throughout his career, Mr. Weisenfeld has worked on a wide range of advisory transactions including acquisitions, sale transactions, and strategic relationships. Selected life sciences transactions include the sale of Seagen to Pfizer for over $44 billion, the sale of Veloxis to Asahi, the acquisition of Alder by Lundbeck, the merger of Keryx with Akebia, the sale of Colucid to Lilly, the sale of Celator to Jazz Pharmaceuticals, Otsuka’s acquisitions of Avanir and Neurovance, and a number of the most prominent reverse mergers. Mr. Weisenfeld is a board member of Public Health Solutions, a New York-based nonprofit. He is also an active alumnus of Cornell University, acting as a member of the scientific advisory committee of Weill Cornell Medical School’s Daedalus Fund for Innovation as well as a member of both the Cornell Brooks School of Public Policy Advisory Council and Cornell Dyson School’s Undergraduate Program Advisory Council. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a B.S. from Cornell University.